Otonomy To Challenge Multi-Dose Ear Drops With Otiprio Expansion Plans
Executive Summary
Otonomy will file for expanded US approval of Otiprio for use in swimmer’s ear on the back of positive top-line Phase III data – the product has the potential to improve on current treatments in terms of dosing, and the news sent its share price up by more than 10%.
You may also be interested in...
Keeping Track: Delay (For Celgene), Delay (For Allergan), Goose! (Approval For Lilly)
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Merck's Follow-On Insulin Edges Closer To Market; Braeburn Submits Another Buprenorphine Depot
The latest drug development news and highlights from our FDA Performance Tracker.
Oncology’s Hold Over The Pharma Pipeline Increases As Growth Slows
The rate of growth of the pharma pipeline slowed last year as oncology and rare diseases tightened their grip on R&D. There are also further signs of China’s rise in importance in the industry.